1999年至2019年胸主动脉腔内修复术长期随访:单中心经验
该单中心研究连续纳入1999年至2019年接受胸主动脉腔内修复术(TEVAR)的256例患者,平均随访5.2±4.5年。主要终点为全因死亡,次要终点为再干预。急诊患者30天死亡率为21.2%(22/104),择期患者为1.75%(2/114)(P < 0.001)。长期随访显示急性主动脉综合征患者早期死亡率高于慢性主动脉疾病患者,但随访结束时差异缩小;多数内漏发生在术后5年内,但新发内漏可持续数十年,需终身监测。
要点
- 急诊TEVAR患者30天死亡率为21.2%(22/104),择期患者为1.75%(2/114)(P < 0.001)。
- 长期随访全因死亡112例(43.8%),再干预29例(11.3%,95%CI 7.7-15.9)。
- 再干预中动脉瘤相关占62.1%,24例(82.8%)再干预发生在术后5年内。
核心结论
- 急性主动脉综合征患者TEVAR术后30天内死亡率高于慢性主动脉疾病患者,但随访结束时差异缩小。
- 多数内漏发生在术后5年内,但先前无内漏的患者数十年后仍可新发内漏,需终身监测。
研究设计与样本
- 单中心连续纳入1999年至2019年接受TEVAR的患者,前瞻性数据库记录基线特征、内漏或动脉瘤增长及死亡。
- 共纳入256例患者,男性占63%,干预时平均年龄66.2±14.5岁,平均随访5.2±4.5年。
- TEVAR指征:急性主动脉综合征40.6%,慢性主动脉疾病44.5%,创伤性破裂14.8%。
- 主要终点为全因死亡,次要终点为再干预;生存和失败分析使用STATA IC 16.0,随访截尾于15年。
主要发现
- 技术成功率为94.1%,左锁骨下动脉覆盖率为27.7%。
- 急诊患者30天死亡率为21.2%(22/104),择期患者为1.75%(2/114)(P < 0.001)。
- 12例患者(4.7%)在治疗后24小时内死亡。
- 长期随访记录全因死亡112例(43.8%),再干预29例(11.3%,95%CI 7.7-15.9),动脉瘤相关再干预占62.1%。
- 24例(82.8%)再干预发生在术后5年内。
临床怎么用
- 原文结论指出急性主动脉综合征患者TEVAR术后早期死亡率高于慢性主动脉疾病患者,但随访结束时差异缩小。
- 原文结论指出多数内漏发生在术后5年内,但新发内漏可持续数十年,需终身监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) was introduced in the early 1990s and long-term follow-up studies are warranted in current guidelines. METHODS: Patients undergoing TEVAR were consecutively included from 1999 to 2019. Thoracic aortic disease includes thoracic aortic aneurysms, aortic dissection, traumatic rupture, penetrating aortic ulcer (PAU), and intramural hematoma (IMH). Our prospective database recorded baseline characteristics, endoleak or aneurysm growth, and death. Patients were included at the time of treatment and censored at death or first reintervention depending on the analysis. Primary end point was all-cause death; secondary end point was reintervention. Survival and failure analyses were done using STATA IC 16.0 and truncated at 15 years of follow-up. RESULTS: Two hundred and fifty six patients were included and 63% were men. Their mean age at intervention was 66.2 ± 14.5 years and they were followed for a mean of 5.2 ± 4.5 years. Indications for TEVAR were acute aortic syndrome in 40.6%, chronic aortic disease in 44.5%, and traumatic rupture in 14.8%. Technical success was seen in 94.1% of the operations, and the left subclavian artery was covered in 27.7%. A 30-day mortality rate was 21.2% (22/104) and 1.75% (2/114) (P < 0.001) for urgent and elective patients, respectively. Twelve patients (4.7%) died within 24 hr of treatment. Overall, long-term mortality recorded 112 (43.8%) deaths, 29 patients had reinterventions (11.3 %, 95% confidence interval: 7.7-15.9), and aneurysms accounted for 62.1% of all reinterventions. Twenty four (82.8%) reinterventions occurred within the first 5 years. CONCLUSIONS: This long-term follow-up study shows excess mortality in patients treated for acute aortic syndrome compared to chronic aortic disease, within the first 30 days; this difference diminishes at the end of follow-up. Most endoleaks occur within the first 5 years, although new endoleaks continue to develop decades after in previous endoleak-free patients calling for lifelong surveillance.
引用
- Liisberg M, Baudier F, Akgül C, et al. Long-Term Thoracic Endovascular Repair Follow-Up from 1999 to 2019: A Single-Center Experience. Ann Vasc Surg. 2022. PMID: 35460855. doi:10.1016/j.avsg.2022.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。